Dynamic changes of hematological and hemostatic parameters in COVID-19 hospitalized patients: Potential role as severity biomarkers for the Chilean population

hematological and hemostatic parameters in COVID-19

  • Pablo Letelier Precision Health Research Laboratory, Departamento de Procesos Diagnósticos y Evaluación, Facultad Ciencias de la Salud, Universidad Católica de Temuco
  • Hugo Delgado Clinical Laboratory, Dr. Hernán Henríquez Aravena Hospital, Temuco, Chile
  • Felipe Garrido Clinical Laboratory, Dr. Hernán Henríquez Aravena Hospital, Temuco, Chile
  • Francisco Quiñones Clinical Laboratory, Dr. Hernán Henríquez Aravena Hospital, Temuco, Chile
  • Andres San Martín Clinical Laboratory, Dr. Hernán Henríquez Aravena Hospital, Temuco, Chile
  • Loreto Hernández Complejo Asistencial Padre Las Casas, Chile
  • Paola Garcés Red Salud Mayor, Temuco, Chile
  • Dina Guzmán Oyarzo School of Medical Technology, Facultad de Medicina y Ciencias, Universidad San Sebastián, Campus Concepción, Chile
  • Rodrigo Boguen Precision Health Research Laboratory, Departamento de Procesos Diagnósticos y Evaluación, Facultad de Ciencias de la Salud, Universidad Católica de Temuco, Chile.
  • Alfonso Hernández Precision Health Research Laboratory, Departamento de Procesos Diagnósticos y Evaluación, Facultad de Ciencias de la Salud, Universidad Católica de Temuco, Chile.
  • Gustavo Medina Precision Health Research Laboratory, Departamento de Procesos Diagnósticos y Evaluación, Facultad de Ciencias de la Salud, Universidad Católica de Temuco, Chile.
  • Patricia Schwerter Department of Mathematical and Physics Sciences, Facultad de Ingeniería, Universidad Católica de Temuco, Chile
  • Neftalí Guzmán Precision Health Research Laboratory, Departamento de Procesos Diagnósticos y Evaluación, Facultad de Ciencias de la Salud, Universidad Católica de Temuco, Chile.
DOI: https://doi.org/10.5937/jomb0-47588
Keywords: COVID-19, SARS-CoV-2, Hematology, Laboratory markers, Prognosis

Abstract


Background: COVID-19 is still a global health issue, there is limited evidence in South America regarding laboratory biomarkers associated with severe disease. The objective of our study was to identify hematological and hemostatic changes associated with severe COVID-19. Methods: A total of 170 hospitalized patients with COVID-19 were included in the study, defining their severity according to established criteria. Demographic, clinical, and laboratory (days 1, 3, 7, 15) data were obtained. We performed a statistical analysis, assuming significance with a value of p < 0.05. We analyzed the correlation between severity and biomarkers and established cut-off values for severe patients through ROC curves, estimating Odds Ratio associated with severe disease. Results: Day 1 was observed significant differences between moderate vs severe patients for leukocytes (WBC), Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and D-dimer, establishing cut-off points for each of them. The markers we found associated to risk of severe disease were WBC (OR=3.2396; p = 0.0003), NLR (OR=5.7084; p < 0.0001), PLR (OR=4.4094; p < 0.0001), Neutrophil (OR=4.1193; p < 0.0001), D-dimer (OR=2.7827; p = 0.0124). Conclusion: The results allow to establish basic laboratory biomarkers associated to severe disease, which could be used as prognostic markers.

 

References

1. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med. 2020;382(26):2534-43.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.
3. Letelier P, Encina N, Morales P, Riffo A, Silva H, Riquelme I, et al. Role of biochemical markers in the monitoring of COVID-19 patients. J Med Biochem. 2021;40(2):115-28.
4. Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, et al. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol. 2022;19(7):475-95.
5. Gajendra S. Spectrum of hematological changes in COVID-19. Am J Blood Res. 2022;12(1):43-53.
6. Thompson S, Bohn MK, Mancini N, Loh TP, Wang CB, Grimmler M, et al. IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients. Clin Chem Lab Med. 2020;58(12):2009-16.
7. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469-72.
8. Pozdnyakova O, Connell NT, Battinelli EM, Connors JM, Fell G, Kim AS. Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. Am J Clin Pathol. 2021;155(3):364-75.
9. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206.
10. Liu L, Zheng Y, Cai L, Wu W, Tang S, Ding Y, et al. Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19. Int J Lab Hematol. 2021;43(2):329-35.
11. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e7.
12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
13. Alhumaid S, Al Mutair A, Al Alawi Z, Al Salman K, Al Dossary N, Omar A, et al. Clinical features and prognostic factors of intensive and non-intensive 1014 COVID-19 patients: an experience cohort from Alahsa, Saudi Arabia. Eur J Med Res. 2021;26(1):47.
14. Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;11(1):8562.
15. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263.
16. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
17. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392-8.
18. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17(3):135-49.
19. Denova-Gutierrez E, Lopez-Gatell H, Alomia-Zegarra JL, Lopez-Ridaura R, Zaragoza-Jimenez CA, Dyer-Leal DD, et al. The Association of Obesity, Type 2 Diabetes, and Hypertension with Severe Coronavirus Disease 2019 on Admission Among Mexican Patients. Obesity (Silver Spring). 2020;28(10):1826-32.
20. Singh R, Rathore SS, Khan H, Karale S, Chawla Y, Iqbal K, et al. Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression. Front Endocrinol (Lausanne). 2022;13:780872.
21. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-4.
22. Slomka A, Kowalewski M, Zekanowska E. Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations. Pathogens. 2020;9(6).
23. Munoz-Rodriguez JR, Gomez-Romero FJ, Perez-Ortiz JM, Lopez-Juarez P, Santiago JL, Serrano-Oviedo L, et al. Characteristics and Risk Factors Associated With Mortality in a Multicenter Spanish Cohort of Patients With COVID-19 Pneumonia. Arch Bronconeumol. 2021;57:34-41.
24. Vial MR, Peters A, Perez I, Spencer-Sandino M, Barbe M, Porte L, et al. Covid-19 in South America: clinical and epidemiological characteristics among 381 patients during the early phase of the pandemic in Santiago, Chile. BMC Infect Dis. 2020;20(1):955.
25. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8.
26. Ding X, Yu Y, Lu B, Huo J, Chen M, Kang Y, et al. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019. Clin Chem Lab Med. 2020;58(8):1365-71.
27. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.
28. Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020;92(9):1533-41.
29. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-8.
30. Palladino M. Complete blood count alterations in COVID-19 patients: A narrative review. Biochem Med (Zagreb). 2021;31(3):030501.
31. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
32. Liu X, Zhang R, He G. Hematological findings in coronavirus disease 2019: indications of progression of disease. Ann Hematol. 2020;99(7):1421-8.
33. Abu-Ismail L, Taha MJJ, Abuawwad MT, Al-Bustanji Y, Al-Shami K, Nashwan A, et al. COVID-19 and Anemia: What Do We Know So Far? Hemoglobin. 2023;47(3):122-9.
34. Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, et al. More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1060-1.
35. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116-20.
36. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
37. Al-Jubury KS, K OA, Alshareef DKJ, Al-Jubury M, Jameel MI. D-dimer and HbA1c levels findings in COVID-19 Iraqi patients. Braz J Biol. 2023;84:e266823.
Published
2024/04/28
Issue
Vol. 43 No. 4 (2024): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2024 Pablo Letelier, Hugo Delgado, Felipe Garrido, Francisco Quiñones, Andres San Martín, Loreto Hernández, Paola Garcés, Dina Guzmán Oyarzo, Rodrigo Boguen, Alfonso Hernández, Gustavo Medina, Patricia Schwerter, Neftalí Guzmán

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.